Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Los Bonos 1 (no aplicable en España), 2 (Marcas y Diseños) y 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentran cerrados desde el 20/08/2025. La solicitud del Bono 4 sigue abierta. Más adelante se informará sobre la reapertura de estos Bonos
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
174
resultados
Última actualización
17/09/2025 [07:45:00]
Resumen de: WO2025186390A1
The present invention refers to an in vitro method for predicting the response of a patient suffering from ulcerative colitis to a treatment with anti-tumor necrosis factor (TNF) antibodies.
Resumen de: WO2025185773A1
Disclosed in the present invention are an antibody targeting TL1A and the use thereof. The antibody of the present invention can be used for blocking the interaction between TL1A and DR3, is helpful for achieving the purpose of intervention from the early stages of inflammation, inhibits immune cells such as effector T cells to release cytokines for promoting an inflammatory response, and provides more possibilities for treatment methods for IBD patients or other TL1A-related diseases.
Resumen de: WO2025185637A1
Provided are methods for determining the risk of, diagnosing, preventing, or treating Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Some embodiments provide kits and computer program products for determining the risk of or diagnosing Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Other example embodiments are described herein. In certain embodiments, the disclosed methods and kits are accurate, cost-effective and non-invasive.
Resumen de: WO2025188870A1
Provided herein are methods of identifying a subject as having an inflammatory bowel disorder, wherein a method includes (a) determining a level of NXPE1 in a biological sample from the subject; and (b) comparing the level of NXPE1 in the biological sample to a reference level, wherein the presence of a level of NXPE1 in the biological sample above the reference level indicates that the subject has an inflammatory bowel disorder.
Resumen de: US2025281553A1
Described herein are bacteriophages that infect and lyse adherent-invasive Escherichia coli (AIEC). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with AIEC or at risk of infection by AIEC, or in the prophylactic or therapeutic treatment of diseases and conditions associated with AIEC, including inflammatory bowel disease (IBD), urinary tract infection (UTI), neonatal meningitis, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, pneumonia, and lung cancer, in a subject in and for other uses described herein.
Resumen de: EP4614151A1
The present invention refers to an in vitro method for predicting the response of a patient suffering from ulcerative colitis to a treatment with anti-tumor necrosis factor (TNF) antibodies.
Resumen de: WO2024094817A1
The present invention relates to a score (TOPOSCORE) for describing eubiosis or dysbiosis in an individual, that can be used, inter alia, for determining if a patient is likely to respond to an immune-oncology treatment, more precisely, a treatment comprising administration of an immune checkpoint inhibitor (ICI). The TOPOSCORE represents a robust biomarker predicting immunosensitivity and immunoresistance to ICI on an individual basis.
Resumen de: AU2023327783A1
Embodiments include a method for detecting small intestinal bacterial overgrowth, SIBO, the method comprising: obtaining data representing a time series of readings from gas sensor hardware housed within an ingestible capsule device orally ingested by a subject, identifying the data corresponding to timing of passage through the small intestine, and determining whether or not the data indicates presence of SIBO.
Resumen de: US2025277269A1
This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
Resumen de: WO2025184435A1
The present invention provides an improved breath analyzer and breath test method to determine the presence of disease in humans, including but not limited to, H. pylori infection, Celiac Disease, Metabolic dysfunction-associated steatohepatitis (MAHD), Inflammatory Bowel Disease (JBD). 'm a subject's digestive tract. In certain embodiments, the present invention provides a universal breath testing platform and methods of testing for diseases of the gastrointestinal tract, the liver, the kidneys, and the lungs, along with testing for cancer, infections, and metabolic diseases.
Resumen de: WO2025181327A1
The present invention relates to a method for determining a need for adjustment of parenteral supplementation, risk of developing acid-base imbalance, and monitoring development of acid-base imbalance in a subject receiving parenteral supplementation and having intestinal insufficiency, such as short bowel. In particular, the present invention relates to determining urinary net acid excretion (NAE) for evaluating acid-base imbalances in subjects having intestinal insufficiency, such as short bowel, in order to determine risk of developing and/or monitoring development of acid-base imbalance, as well as adjustment of parenteral supplementation.
Resumen de: WO2025181330A1
The present disclosure relates to dosage regimens for glucagon-like-peptide-2 (GLP-2) analogs, e.g., apraglutide, in a subject in need thereof, e.g., a subject with short bowel syndrome (SBS).
Resumen de: EP4610657A1
Provided are a method for detecting an immune-mediated inflammatory disease characterized by an increase in expression of MMP12, in a subject, a diagnostic drug containing a substance that specifically interacts with MMP12, and a therapeutic agent containing an MMP12 inhibitory substance.
Resumen de: MX2025009868A
The present disclosure generally relates to methods, and diagnostic applications, for the treatment of ulcerative colitis. More particularly the methods and diagnostic applications of the present invention relate to expression profiles of certain gene transcripts in ulcerative colitis patients and the usefulness of the expression profiles of these gene transcripts for the treatment, and/or diagnostic use in a subgroup of patients having ulcerative colitis.
Resumen de: AU2024213250A1
The present disclosure provides compositions and methods for using stool-derived, eukaryotic, nucleic acid biomarkers to diagnose disease, assess disease activity, monitor mucosal healing, and predict therapeutic response. The described biomarkers can be used by practitioners to better diagnose, manage, and treat inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).
Resumen de: WO2025177282A1
A system for predicting a response to nutritional therapy for treating Crohn's Disease (CD), including a computer with a processor and memory, a machine learning module, wherein the machine learning module is programed to train a model by accepting a training data set comprising multiomics data of subjects with Crohn's disease that were treated by exclusive enteral nutrition (EEN) and a determination if each subject was a responder that successfully responded to the treatment or was a non-responder that unsuccessfully responded to the treatment, and wherein the machine learning module uses the trained model to accept multiomics data of a patient and predict if the patient is a responder or a non-responder.
Resumen de: WO2025176879A1
The present invention relates to methods of immunoassay for detecting or monitoring inflammatory bowel disease or a severity thereof in a patient. In certain embodiments, the inflammatory bowel disease may be ulcerative colitis.
Resumen de: WO2025179106A1
A system or method for a combination assay of human antibodies to Mycobacterium avium subsp. paratuberculosis (MAP) and cytokines for the diagnosis of Crohn's disease, tuberculosis, and other bacterial diseases in symptomatic and asymptomatic individuals is provided herein. The system or method describes generally using a combination of human antibodies to MAP useful for the detection of a MAP infection in human blood samples and cytokines secreted by the human host with a MAP infection to provide a simple and rapid serological test which can diagnose patients with Crohn's disease and can aid in the selection of patients for certain antibiotic therapies. A similar system could be used for the diagnosis and selection for therapy of tuberculosis and other mycobacterial or bacterial diseases.
Resumen de: WO2025176817A1
The present invention relates to diagnostic and prognostic methods and their use in diagnosing or predicting disease progression in a subject with Ulcerative Colitis (UC). More particularly, the present invention relates to a gene expression signature and the use thereof in determining the likelihood of progression of Ulcerative Colitis in a subject, as well as compositions for the detection thereof. The invention also extends to the use of biomarkers as targets to improve the treatment of Ulcerative Colitis in patients.
Resumen de: US2025271429A1
A system or method for a combination assay of human antibodies to Mycobacterium avium subsp. paratuberculosis (MAP) and cytokines for the diagnosis of Crohn's disease, tuberculosis, and other bacterial diseases in symptomatic and asymptomatic individuals is provided herein. The system or method describes generally using a combination of human antibodies to MAP useful for the detection of a MAP infection in human blood samples and cytokines secreted by the human host with a MAP infection to provide a simple and rapid serological test which can diagnose patients with Crohn's disease and can aid in the selection of patients for certain antibiotic therapies. A similar system could be used for the diagnosis and selection for therapy of tuberculosis and other mycobacterial or bacterial diseases.
Resumen de: AU2023364180A1
Provided herein is a peptide array comprising a plurality of flagellin peptides corresponding to highly conserved peptide regions. For example, the peptide array comprises a plurality of
Resumen de: EP4607197A1
Provided is an examination method for irAE enteritis, said examination method comprising a detection step for detecting, as an indicator of ulcerous colitis-like irAE enteritis, an antibody that immunologically reacts with a fragment of, or the entirety of, integrin αvβ6 in a specimen.
Resumen de: EP4606910A1
The present invention relates to diagnostic and prognostic methods and their use in diagnosing or predicting disease progression in a subject with Ulcerative Colitis (UC). More particularly, the present invention relates to a gene expression signature and the use thereof in determining the likelihood of progression of Ulcerative Colitis in a subject, as well as compositions for the detection thereof. The invention also extends to the use of biomarkers as targets to improve the treatment of Ulcerative Colitis in patients.
Resumen de: US2025262251A1
Provided are methods for treating an individual who has inflammatory bowel diseases (IBD and) spondyloarthritis by selecting the individual based on a determination that that the gastrointestinal system of the individual comprises a microbiome lacking bacteria that provide functional folate trap, and administering to the individual sulfasalazine and bacteria that include a functional folate trap to thereby treat the IBD.
Nº publicación: AU2024230939A1 21/08/2025
Solicitante:
CEDARS SINAI MEDICAL CENTER
CEDARS-SINAI MEDICAL CENTER
Resumen de: AU2024230939A1
Described herein are methods of reducing CD3-dependent T cell signaling in a subject in need thereof. Also described are method of increasing T-regulatory (Treg) cells, or decreasing T-helper 17 (Th17) cells. These methods involve administering butyrophilin A2 (BTN2A2), a BTN2A2 fragment thereof, a BTN2A2-related isoform, or a BTN2A2-related isoform fragment, or a conjugate or fusion polypeptide comprising any of the foregoing to the subject. These methods are beneficial for patients with autoimmune disorders and inflammatory disorders such as allergy, asthma, glomerulonephritis, inflammatory bowel disease, rheumatoid arthritis, an autoimmune or inflammatory neurological disease, antibody mediated transplant rejection, infantile cholestasis, haemophagocytic lymphohistiocytosis, erythrocytic haemophagocytosis, malnutrition, systemic lupus erythematosus (lupus), psoriasis, myasthenia gravis or HIV. Further described are fusion proteins having BTN2A2 and an Fc domain.
BOPI
Sede Electrónica
